Clinical Cardiology Alert – July 1, 2010
July 1, 2010
View Issues
-
Complete Revascularization with PCI in Patients with LV Dysfunction
Ischemic cardiomyopathy remains a frequent cause of heart failure. Management of patients with coronary artery disease with LV dysfunction has traditionally been achieved with coronary artery bypass graft surgery (CABG). More recently, percutaneous coronary intervention (PCI) has shown similar results to CABG in patients with multi-vessel coronary artery disease. -
LV Function Deteriorates in Non-STEMI Patients Awaiting Cardiac Catheterization
The optimal timing of cardiac catheterization for patients suffering non-ST segment elevation myocardial infarction (nonSTEMI) remains a subject of debate. -
ACE Inhibitors in Acute Myocardial Infarction
The use of angiotensin converting enzyme (ACE) inhibitors in all acute myocardial infarction (MI) patients is controversial. -
Prognosis of No-reflow Phenomenon
Little is known about the long-term prognosis of the no-reflow phenomenon after percutaneous intervention (PCI) for acute ST elevation myocardial infarction (STEMI). -
Dronedarone vs. Amiodarone in Atrial Fibrillation
Dronedarone is an antiarrhythmic drug with structural and electrophysiologic similarities to amiodarone that was released in 2009. Dronedarone's structure includes a benzofuranyl ring but, unlike amiodarone, the ring is not iodinated. -
Epicardial Ablation Experience
In this study, Sacher and colleagues, from three well-know ablation centers, report their experience with epicardial ventricular tachycardia (VT) ablation. -
Ambulatory Cardiac Telemetry
Ambulatory cardiac telemetry uses a cellular phone monitor to continuously receive transmissions from a sensor on the patient, interpret them, and send ECG strips, considered to be possibly dangerous arrhythmias, to a central station for review and possible intervention. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
New reports about proton pump inhibitors and the effects of gastric suppression, pioglitazone vs vitamin E for non-alcoholic steatohepatitis, metformin and vitamin B12 deficiency, and FDA Actions